{"denoms":[{"counts":[{"groupId":"BG000","value":"157"},{"groupId":"BG001","value":"157"},{"groupId":"BG002","value":"93"},{"groupId":"BG003","value":"91"},{"groupId":"BG004","value":"498"}],"units":"Participants"}],"groups":[{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks","id":"BG000","title":"Cohort 1 Vemurafenib"},{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"BG001","title":"Cohort 1 Placebo"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks","id":"BG002","title":"Cohort 2 Vemurafenib"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"BG003","title":"Cohort 2 Placebo"},{"description":"Total of all reporting groups","id":"BG004","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.4","value":"50.7"},{"groupId":"BG001","spread":"12.7","value":"49.6"},{"groupId":"BG002","spread":"14.1","value":"51.6"},{"groupId":"BG003","spread":"12.9","value":"49.1"},{"groupId":"BG004","spread":"12.9","value":"50.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"The intent-to-treat (ITT) population included all participants enrolled in the study, whether or not they had received study medication.","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"32"},{"groupId":"BG004","value":"215"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"59"},{"groupId":"BG004","value":"283"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The intent-to-treat (ITT) population included all participants enrolled in the study, whether or not they had received study medication.","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"25"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"79"},{"groupId":"BG003","value":"80"},{"groupId":"BG004","value":"445"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"28"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The intent-to-treat (ITT) population included all participants enrolled in the study, whether or not they had received study medication.","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"150"},{"groupId":"BG001","value":"150"},{"groupId":"BG002","value":"84"},{"groupId":"BG003","value":"81"},{"groupId":"BG004","value":"465"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"6"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"}]}],"title":"Multiple"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"26"}]}],"title":"Unknown"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The intent-to-treat (ITT) population included all participants enrolled in the study, whether or not they had received study medication.","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"The intent-to-treat (ITT) population included all participants enrolled in the study, whether or not they had received study medication."}